Yasutsuna Sasaki

Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial

Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto et al. · The Lancet Oncology · 2013 · 252 citations

Oncology, Randomised Phase 3, Bevacizumab Versus S-1 +8

Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial

Kohei Shitara, Atsuo Takashima, Kazumasa Fujitani et al. · ˜The œLancet. Gastroenterology & hepatology · 2017 · 215 citations

Gastrointestinal Oncology, Medicine, Advanced Gastric Cancer +5

A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors

Tomohide Tamura, Hironobu Minami, Yasuhide Yamada et al. · Journal of Thoracic Oncology · 2006 · 130 citations · Full text

Dose-escalation Study, Medicine, Malignant Tumors +8

Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer

Taroh Satoh, Kyung Hee Lee, Sun Young Rha et al. · Gastric Cancer · 2014 · 114 citations · Full text

Genotype‐directed, dose‐finding study of irinotecan in cancer patients with <i>UGT1A1*28</i> and/or <i>UGT1A1*6</i> polymorphisms

Taroh Satoh, Takashi Ura, Yasuhide Yamada et al. · Cancer Science · 2011 · 103 citations · Full text

Irinotecan-induced Severe Neutropenia, Fixed Dose, Genetic Epidemiology +16